Neurological pathway illustration showing myelin sheath repair; MRI brain imaging; conceptual neuron and axon repair imagery in MS.

Pheno Therapeutics has received US FDA IND clearance for PTD802, enabling first-in-human clinical trials of its lead remyelination therapy for multiple sclerosis.

Pheno Therapeutics has secured US Food and Drug Administration clearance of its Investigational New Drug application for PTD802, allowing the company to begin first-in-human clinical testing of its lead programme in multiple sclerosis.

The Edinburgh-based biotech said the clearance represents a key step forward in its clinical strategy, with chief executive Fraser Murray describing it as “an important milestone for our PTD802 programme” and a move closer to developing “an effective treatment for neurological diseases associated with demyelination.”

PTD802 is a selective GPR17 antagonist designed to promote remyelination in neurological disease, with initial development focused on multiple sclerosis, a condition characterised by immune-mediated damage to the myelin sheath surrounding nerve fibres in the central nervous system.

The disease leads to progressive neurological dysfunction, and while current therapies can control inflammatory activity, they do not address the underlying loss of myelin or prevent long-term neurodegeneration.

Pheno said PTD802 is the first GPR17 antagonist programme to receive IND clearance, positioning it as a potential first-in-class approach in a new neuroprotective mechanism.

Murray added that the company is “leading the way” in this emerging therapeutic class, noting that the mechanism has the potential to deliver meaningful benefit in multiple sclerosis and other demyelinating conditions.

The IND clearance follows a UK clinical trial authorisation granted by the Medicines and Healthcare products Regulatory Agency in 2025, allowing the programme to progress through early-stage development across multiple jurisdictions.

The planned first-in-human study will evaluate the safety and tolerability of PTD802 in healthy volunteers, providing initial clinical data on the compound’s pharmacological profile.

PTD802 was developed under an exclusive worldwide licence from UCB and represents a small molecule approach to stimulating repair processes in the central nervous system.

Multiple sclerosis affects millions globally and remains an area of high unmet need, particularly for therapies capable of repairing rather than solely suppressing immune activity.

The company’s approach targets GPR17, a receptor implicated in the regulation of oligodendrocyte maturation and myelin repair, representing a novel pathway in neuroregenerative drug development.

Pheno said the clearance strengthens its intellectual property position in the US and supports progression of its wider neurological disease pipeline.